Literature DB >> 1527858

Human immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-stimulated gp120 release.

E A Berger1, J R Sisler, P L Earl.   

Abstract

The ability of soluble forms of CD4 to induce gp120 release from the human immunodeficiency virus type 1 envelope glycoprotein complex may reflect molecular events associated with membrane fusion. The third hypervariable (V3) region of gp120 appears to play a role in fusion independent of CD4 binding. We demonstrate herein that envelope glycoprotein molecules rendered fusion defective by mutations in conserved residues within the V3 region nevertheless undergo efficient soluble CD4-induced gp120 release.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1527858      PMCID: PMC283674     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

Review 1.  Structural and functional features of the HIV envelope glycoprotein and considerations for vaccine development.

Authors:  S D Putney; J Rusche; K Javaherian; T Matthews; D Bolognesi
Journal:  Biotechnology       Date:  1990

2.  Binding to CD4 of synthetic peptides patterned on the principal neutralizing domain of the HIV-1 envelope protein.

Authors:  M Autiero; P Abrescia; M Dettin; C Di Bello; J Guardiola
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

3.  Functional roles of the V3 hypervariable region of HIV-1 gp160 in the processing of gp160 and in the formation of syncytia in CD4+ cells.

Authors:  B M Travis; T I Dykers; D Hewgill; J Ledbetter; T T Tsu; S L Hu; J B Lewis
Journal:  Virology       Date:  1992-01       Impact factor: 3.616

4.  The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism.

Authors:  A J Cann; M J Churcher; M Boyd; W O'Brien; J Q Zhao; J Zack; I S Chen
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

5.  Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants.

Authors:  E Helseth; M Kowalski; D Gabuzda; U Olshevsky; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

6.  The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides.

Authors:  D Batinić; F A Robey
Journal:  J Biol Chem       Date:  1992-04-05       Impact factor: 5.157

7.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4.

Authors:  J P Moore; J A McKeating; R A Weiss; Q J Sattentau
Journal:  Science       Date:  1990-11-23       Impact factor: 47.728

8.  Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo.

Authors:  P Westervelt; D B Trowbridge; L G Epstein; B M Blumberg; Y Li; B H Hahn; G M Shaw; R W Price; L Ratner
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4.

Authors:  W A O'Brien; I S Chen; D D Ho; E S Daar
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role of the complementarity-determining region 3-like region in membrane fusion.

Authors:  E A Berger; J D Lifson; L E Eiden
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

View more
  18 in total

1.  Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein.

Authors:  R Wyatt; E Desjardin; U Olshevsky; C Nixon; J Binley; V Olshevsky; J Sodroski
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants.

Authors:  A Carrillo; L Ratner
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

3.  Adaptation of human immunodeficiency virus type 1 to cells expressing a binding-deficient CD4 mutant (lysine 46 to aspartic acid).

Authors:  H R Choe; J Sodroski
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

4.  Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability.

Authors:  L Stamatatos; C Cheng-Mayer
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

5.  The "V3" domain is a determinant of simian immunodeficiency virus cell tropism.

Authors:  F Kirchhoff; K Mori; R C Desrosiers
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

6.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

7.  gp120-independent fusion mediated by the human immunodeficiency virus type 1 gp41 envelope glycoprotein: a reassessment.

Authors:  L Marcon; J Sodroski
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

9.  Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.

Authors:  R Wyatt; N Sullivan; M Thali; H Repke; D Ho; J Robinson; M Posner; J Sodroski
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

10.  Calcium ions are required for cell fusion mediated by the CD4-human immunodeficiency virus type 1 envelope glycoprotein interaction.

Authors:  D S Dimitrov; C C Broder; E A Berger; R Blumenthal
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.